Table 1 Baseline and clinical characteristics of patients

Male gender

43(70.5%)

48(72.7%)

0.78

Age, years

66.84 ± 7.11

69.94 ± 6.61

0.012

BMI, Kg/m²

24.61(23.07,26.42)

24.60(21.73,28.20)

0.813

LVEF,%

62(58,65)

58(45,62)

< 0.001

Hypertension

35(57.4%)

38(57.6%)

1

 I

8(13.1%)

8(12.1%)

0.866

 II

5(8.2%)

9(13.6%)

0.328

 III

22(36.1%)

21(33.3%)

0.746

Diabetes

14(23%)

23(34.8%)

0.14

Cerebral infarction

11(18%)

18(27.3%)

0.215

Chronic renal insufficiency

3(4.9%)

3(3%)

0.928

Smoking history

31(50.8%)

34(51.5%)

0.672

Family history of coronary heart disease

9(14.8%)

10(15.2%)

0.95

History of chemical drug therapy

16(26.2%)

14(21.2%)

0.506

Radiotherapy history

4(6.6%)

2(3.0%)

0.605

Hyperlipemia

21(34.4%)

22(33.3%)

0.897

Primary diagnosis of CHD

 Stable angina

39(63.9%)

24(36.4%)

0.002

 Unstable angina

11(18.0%)

22(33.3%)

0.049

 STEMI

9(14.8%)

12(18.2%)

0.603

 NSTEMI

2(3.3%)

8(12.1%)

0.129

Clinical laboratory testing

 CK

62.70(49.90,90.68)

59.60(37.20,80.65)

0.71

 CKMB, ng/ml

9.52(8.03,13.14)

8.61(6.75,11.98)

0.20

 TNI, ng/ml

0.012(0.012,0.030)

0.012(0.012,0.22)

0.45

 BNP, pg/ml

278(118.5,358.5)

261(85,744)

0.56

 TC, mmol/

3.79(3.4,4.53)

3.76(3.2,4.5)

0.31

 TG, mmol/l

1.35(1.12,1.66)

1.25(1, 1.7,)

0.59

 HDL‑C, mmol/l

1.20 ± 0.35

1.09 ± 0.27

0.293

 LDL‑C, mmol/l

2.38 ± 0.80

2.13 ± 0.66

0.286

Oral medication status for CHD

 Aspirin

43(70.5%)

62(93.9%)

< 0.001

 Indobufen

18(29.5%)

4(6.1%)

< 0.001

 Clopidogrel

51(83.6%)

54(81.8%)

0.79

 Ticagrelor

9(14.8%)

10(15.2%)

0.95

 Nitrate esters

43(70.5%)

56(84.8%)

0.051

 Statins

61(100%)

65(98.5%)

1

 Beta-blockers

24(39.3%)

34(51.5%)

0.169

 ACEI/ARB

25(41.0%)

29(43.9%)

0.736

 ARNI

8(13.1%)

14(21.2%)

0.228